Commentary

Time to reconsider urate: Neuroprotective potential may prevail on cardiovascular risk in animal models and clinical trials

Martina Petruzzo, Marcello Moccia *

Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University, Naples, Italy

In this issue of EBioMedicine, Chen and colleagues investigated the association between urate, the anionic form of uric acid, and blood pressure (BP), by studying three groups of genetically engineered mice with different levels of urate, and by reanalysing data from a clinical trial using inosine to increase urate levels in Parkinson’s disease (PD) [1,2].

Urate is the enzymatic end-product of purine metabolism in apes and humans, and is traditionally thought to be a cardiovascular risk factor, contributing to chronic inflammation within the endothelium and, ultimately, to its dysfunction with subsequently higher BP [3,4]. However, higher urate is not necessarily a cause of hypertension, nor its consequence, and could be merely an association. Based on this, authors acquired BP measurements from three complementary lines of genetically engineered mice: urate oxidase (UOx) conditional knockout (cKO), global KO (gKO), and transgenic (Tg) mice with mildly elevated, markedly elevated, and substantially reduced serum urate, respectively. These knockout models were specifically selected to mimic the evolutionary mutations in UOx gene, making them as much “humanized” as an animal model could possibly be. Also, authors re-analysed data from the SURE-PD, a phase 2 clinical trial aiming at evaluating safety of inosine in increasing urate levels in early PD. [1] Results consistently did not support any positive association between long-term urate elevation and BP variations in neither animal models nor generally-healthy early PD. [2] Biological and clinical relevance of these findings go far beyond this study, and will impact on basic and clinical research on neurodegenerative diseases, where urate-elevating strategies have been tested.

Urate accounts for 60% plasma antioxidant capacity and acts as a scavenger of free radicals, exerting neuroprotective effects on animal models of brain/spinal cord injury, multiple sclerosis (MS), and stroke [4,5]. Further neuroprotectant evidence comes from epidemiological studies showing lower levels of urate being associated with a higher risk of developing amyotrophic lateral sclerosis (ALS) [5], multiple sclerosis (MS) [6], multiple system atrophy (MSA) [7], and PD. [4] Not least, clinical observational studies found lower levels of urate being associated with worse outcomes in MS [8], MSA [7], PD [4,9], and stroke [10]. Based on this, urate-elevating strategies have been tested for safety and efficacy in phase 2 and, more recently, phase 3 clinical trials (Table 1). Most of these studies have used an urate precursor, inosine, that is taken orally and rapidly metabolized to urate [5]. Overall, phase 2 clinical trials proved inosine safe in elevating plasma and CSF urate in the long term, and did not support any association between elevated urate and any cardiovascular comorbidity (e.g., hypertensive, hyperglycaemic, dyslipidaemic and obesity components of metabolic syndrome) [1,6]. Encouraging clinical results were shown in a phase 2/3 clinical trial (URICO-ICTUS) where the combination of intravenous urate with thrombolysis in acute ischemic stroke resulted in improved clinical outcomes, especially in women and in patients more vulnerable to oxidative stress and reperfusion injury (e.g., hyperglycaemia at stroke onset) [10]. Further clinical results are expected from the ongoing phase 3 clinical trial in PD (SURE-PD3), potentially leading to the first disease-modifying therapy for PD.

In conclusion, we feel we need to thank Chen and colleagues for their elegant study, providing basic and clinical scientists with evidence suggesting there is little risk of increasing blood pressure while applying urate-elevating strategies, that, thus, could be further moved towards treatment of neurodegenerative diseases.

DOI of original article: https://doi.org/10.1016/j.ebiom.2018.10.039.
* Corresponding author.
E-mail address: marcello.moccia@unina.it (M. Moccia).
Acknowledgements, funding and conflict of interest

The authors declare no conflict of interest.

Martina Petruzzo has nothing to disclose. Marcello Moccia has received research grants from ECTRIMS-MAGNIMS and Merck.

References

[1] The Parkinson Study Group SURE-PD Investigators. Inosine to increase serum and cerebrospinal fluid urate in parkinson disease: a randomized clinical trial. JAMA Neurol 2014;71:141–50.
[2] Chen X, Umeh C, Tainsh R, et al. Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease. ElBioMedicine 2018;37:259–68.
[3] Maruhashi T, Hisatome I, Kihara Y, Higashi Y. Hyperuricemia and endothelial function: From molecular background to clinical perspectives. Atherosclerosis 2018;278:226–31.
[4] Crotty GF, Ascherio A, Schwarzchild MA. Targeting urate to reduce oxidative stress in Parkinson disease. Exp Neurol 2017;298:210–24.
[5] Paganoni S, Schwarzchild MA. Urate as a marker of risk and progression of neurodegenerative disease. Neurotherapeutics 2017;14:148–53.
[6] Muñoz García D, Midaglia L, Martinez Vilela J, et al. Associated Inosine to interferon: Results of a clinical trial in multiple sclerosis. Acta Neurol Scand 2015;131:405–10.
[7] Zhang X, Liu DS, An CY, et al. Association between serum uric acid level and multiple system atrophy: A meta-analysis. Clin Neurol Neurosurg 2018;169:16–20.
[8] Moccia M, Lanzillo R, Costabile T, et al. Uric acid in relapsing-remitting multiple sclerosis: A 2-year longitudinal study. J Neurol 2015;262:961–7.
[9] Moccia M, Picillo M, Erro R, et al. Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients? Parkinsonism Relat Disord 2014;20:772–5.
[10] Chamorro Á, Amaro S, Castellanos M, et al. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): A randomised, double-blind phase 2b/3 trial. Lancet Neurol 2014;13:453–60.